LipoGalen®
A New Generation of Functional Lipid-Based Excipients.
Innovative polyglycerol ester technology designed to expand the possibilities of modern pharmaceutical formulation development.
Designed for the Challenges of Modern Formulations
LipoGalen® was developed to address limitations commonly associated with conventional lipid excipients. Based on innovative polyglycerol ester technology, the platform combines functional versatility with excellent processing characteristics.
Unlike traditional glyceride systems, LipoGalen® materials crystallize in a stable modification without polymorphic transitions. In addition, key properties such as wettability, water uptake, melting behavior and HLB profile can be tailored to meet specific formulation requirements.
This unique combination creates opportunities for formulators seeking innovative solutions for advanced drug delivery systems and next-generation manufacturing technologies.
LipoGalen® 144
LipoGalen® 144 is the first product of the platform and was specifically developed as an innovative excipient for suppository and ovule formulations.
Combining hydrophilic and lipophilic functionality within a single lipid-based system, LipoGalen® 144 offers stable water uptake characteristics and enhanced mucosal adhesion potential, creating new formulation opportunities for rectal and vaginal drug delivery.
In exploratory formulation studies, LipoGalen® demonstrated the ability to incorporate hydrophilic and lipophilic active pharmaceutical ingredients individually as well as in combination, without the need for additional solubilizers or emulsifying agents.
Furthermore, vaginal ovules formulated with LipoGalen® 144 and lactic acid were evaluated in a human user panel and demonstrated a user experience and comfort profile comparable to leading commercially available benchmark products.
Application Opportunities/ Emerging Applications
The LipoGalen® technology platform is being evaluated for a broad range of pharmaceutical applications, including:
- Controlled drug release systems
- Bioavailability enhancement of poorly soluble APIs
- Hot-melt extrusion
- Hot-melt coating and taste masking
- Lipid nanoparticles
- Nanoemulsions
- Continuous manufacturing
- 3D printing and additive manufacturing
- Functional coatings
- Advanced drug delivery systems
Please get in touch with us to get a recommendation for your project!
Looking Ahead
LipoGalen® represents a growing technology platform designed to support future pharmaceutical innovation. Ongoing development activities focus on expanding the product portfolio and enabling new application areas where functional lipid excipients can contribute to improved formulation performance.
LipoGalen®. Expanding the possibilities of lipid-based excipients.
October 2025
LipoGalen®
Our innovative polyglycerol esters now have a name – We’re thrilled to introduce LipoGalen® as the brand name for our new family of Functional Lipid-Based Excipients.
In the last IOI newsletter, we announced the launch of our new family of functional, lipid-based excipients, the polyglycerol esters.
After intensive and dedicated research and development plus countless hours of brainstorming sessions, IOI Oleo GmbH finally unveils something truly special:
LipoGalen® will be the name of our new brand, which will be making its debut at CPHI Frankfurt.
This launch marks a major milestone for us, and we couldn’t be prouder to share it with you. LipoGalen® was born out of a deep understanding of the evolving challenges in pharmaceutical formulation. In contrast to common triglycerides, it crystallizes in one stable modification and does not show any polymorphism.
LipoGalen™ offers a versatile, forward-thinking platform designed to empower innovation across a wide range of applications:
We warmly invite you to join us at CPHI Frankfurt to discover how LipoGalen® can elevate your formulation strategies and open up exciting new possibilities in drug delivery.
Let’s shape the future of pharmaceutical development — together.
A new generation of
lipid based excipients
What if a new generation of lipid-based excipients could lift advanced pharmaceutical drug development with poorly soluble APIs to its next level by providing a built-in fit-for-purpose feature for advanced processes such as hot melt extrusion, hot melt coating, particle engineering and 3D-printing?
More than 75% of new chemical entities are poorly soluble and require bioavailability-enhancing excipients.
The application of excipients in advanced pharmaceutical processes, aligned with advanced approaches towards personalized medicine, requires special features.
Lipid-based excipients (LBEs) are “natural contenders” for the tasks.
However, until now, it has not been possible to fully exploit the potential of LBEs.
The main challenge is the unstable solid state of current LBEs, e.g. polymorphism, leading to instability of the final dosage form.
Compared to polymers, the low melting temperature of liquids, combined with highly crystalline arrangement, limits their application in advanced pharmaceutical processes.
How this new generation of LBEs could serve your fit for purpose needs is described in the publications and posters listed below.
Novel approach for overcoming the stability challenges of lipid-based excipients
Part 1: Screening of solid-state and physical properties of polyglycerol esters of fatty acids as advanced pharmaceutical excipients
Carolina Corzo a,b, Diogo Gomes Lopes a, Dirk Lochmann c, Sebastian Reyer c, Michael Stehr c, Sharareh Salar-Behzadi a,b
Novel approach for overcoming the stability challenges of lipid-based excipients
Part 2: Application of polyglycerol esters of fatty acids as hot melt coating excipients
Sharareh Salar-Behzadi a, Carolina Corzo a, Diogo Gomes Lopes a, Claudia Meindl c, Dirk Lochmann d, Sebastian Reyer d
Novel approach for overcoming the stability challenges of lipid-based excipients
Part 3: Application of polyglycerol esters of fatty acids for the next generation of solid lipid nanoparticles
Carolina Corzo a,b, Claudia Meindl c, Dirk Lochmann d, Sebastian Reyer d, Sharareh Salar-Behzadi a,b
Eleonore Fröhlich a,b, Kristin Öhlinger b, Claudia Meindl b, Carolina Corzo c, Dirk Lochmann d, Sebastian Reyer d, Sharareh Salar-Behzadi a,c
Carolina Corzo a,b, Diogo Gomes Lopes a, Dirk Lochmann c, Sebastian Reyer c, Michael Stehr c, Sharareh Salar-Behzadi a,b
Sharareh Salar-Behzadi a, Carolina Corzo a, Diogo Gomes Lopes a, Claudia Meindl c, Dirk Lochmann d, Sebastian Reyer d
Carolina Corzo a,b, Claudia Meindl c, Dirk Lochmann d, Sebastian Reyer d, Sharareh Salar-Behzadi a,b
Eleonore Fröhlich a,b, Kristin Öhlinger b, Claudia Meindl b, Carolina Corzo c, Dirk Lochmann d, Sebastian Reyer d, Sharareh Salar-Behzadi a,c
If you have further specific needs or questions or in case you have already been confronted with the unstable solid state of existing LBEs in your formulation, we are happy to support you to overcome the challenge of polymorphism.
Please talk to us at the booth.
